The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) plays a critical role in ensuring the safety, quality, and efficacy of medicines and medical devices. MHRA inspections are often a key step in bringing new therapies to market, but poor preparation can result in delays or regulatory setbacks.

Here, we outline the types of MHRA inspections, provide an overview of the essential steps and documents, and discuss challenges and how to overcome them to streamline your MHRA inspection process.

Types of MHRA inspections

There are two main MHRA inspection types. They include:

• Statutory Good Clinical Practice (GCP) Inspection (a “routine” inspection): This inspection is performed as part of the risk-based compliance program and can be either systems-based or trial specific. Inspectors examine how an organization’s trial procedures are applied, considering previous inspection history, organizational changes, or intelligence from other external sources. Sponsors are usually notified six months ahead of time.

• Triggered Inspection: Triggered inspections are initiated by concerns regarding a clinical trial’s conduct, often from sources like serious breach notifications, whistleblowers, or other MHRA departments. The nature of the information determines the level of notice provided, which may be short or none at all.

Essential steps and documents

The MHRA inspection process consists of three primary phases: planning, inspection, and reporting.

• In the planning phase, sponsors receive an “Advance Notice of Statutory Inspection” notification, prepare an Inspection Dossier, and develop an Inspection Plan.

• The inspection phase involves the main site inspection.

• The reporting phase comprises issuing an Inspection Report and identifying Corrective and Preventive Actions (CAPA).

Strategies to streamline the inspection process

Apply the framework for engagement

Define clear duties and responsibilities, emphasize collaboration, and foster productive dialogue. This approach includes four considerations: steering group and communication, resource management and flexibility, documentation, preparation and strategic output. (We will discuss this framework in detail in our upcoming webinar, click the link below to register).

Prepare supportive documents

Create supportive documents that enable quick access to detailed and precise information during high-pressure situations, enhance understanding of the procedures and trial materials under review, and prepare tools and responses for anticipated critical discussion points.

Ensure staff is adequately trained

Mandatory training on current and historical versions of quality assurance documents, including SOPs, WIs, and related tools, is required to ensure understanding of both current processes and those used at the time of production of the deliverables for each study inspected.

Use live demos or “show and tell” sessions

Live demos can help visualize the process and ensure it is understood by the inspector as well as provide the opportunity to delve into the details.

Final takeaways

Navigating MHRA inspections requires a proactive approach, strategic preparation, and a deep understanding of evolving regulatory expectations. By leveraging innovative strategies, organizations can streamline their inspection readiness and enhance compliance outcomes. Equally crucial is the establishment of a well-defined framework that fosters effective collaboration among all stakeholders — sponsors and key vendors alike — ensuring a streamlined and coordinated approach to the inspection process.

Want to learn more?

Join Stephanie Dontenville and Nicolas Rouillé for their upcoming webinar to gain practical insights from Cytel’s MHRA inspection experience. Learn how to prepare thoroughly, execute precisely, and turn post-inspection feedback into innovation.

Share Via